Researchers at Stanford have developed a strategy to improve the efficacy of antibiotics by conjugating the antibiotic to a guanidinium-rich molecular transporter (GR-MoTr).
Researchers at Stanford have developed prodrug derivatives of protein kinase C (PKC) modulators that have lower toxicity and are more effective than the parent compound. PKC modulators are being developed to treat a variety of diseases.